Investigational New Drugs

, Volume 1, Issue 3, pp 249–252 | Cite as

The treatment of acute leukemia with continuous infusion L-Alanosine

  • James K. Weick
  • Bill L. Tranum
  • Francis S. Morrison


L-Alanosine, an antitumor antibiotic was administered by members of the Southwest Oncology Group (SWOG) to 22 patients with resistant acute non-lymphocytic leukemia. The drug was administered by continuous infusion for five days at a starting dose of 125 mg/m2/day. Mucositis was dose-limiting in 15 patients and no marrow aplasia was attained. As administered, L-Alanosine is not an effective single agent in acute leukemia.

Key words

acute leukemia chemotherapy L-Alanosine Phase II 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murthy YKS, Thieman JE, Coronelli C, Sensi P: Alanosine, a new antiviral and antitumor agent isolated from a streptomyces. Nature 211:1198–1199, 1966Google Scholar
  2. 2.
    Investigational Drug Branch, CTEP, NCI. Clinical Brochure, L-Alanosine, November, 1977Google Scholar
  3. 3.
    Dosik GM, Stewart D, Valdivieso M, Burgess MA, Bodey GP: Phase I study of L-Alanosine using a daily × 3 schedule. Cancer Treat Rep 66:73–76, 1982Google Scholar
  4. 4.
    Goldsmith MA, Ohnuma T, Spigelman M, Greenspan EM, Holland JF: Phase I study of L-Alanosine (NSC 15353). Cancer 51:378–380, 1983Google Scholar
  5. 5.
    Kovatch J: Phase I Meeting, NCI, March, 1980Google Scholar
  6. 6.
    Graff JC, Plagemann PGW: Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. Cancer Res 36:1428–1400, 1976Google Scholar
  7. 7.
    Interim Report, Mayo Clinic, 11/28/80Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • James K. Weick
    • 1
  • Bill L. Tranum
    • 2
  • Francis S. Morrison
    • 3
  1. 1.Cleveland Clinic FoundationClevelandUSA
  2. 2.University of Arkansas for Medical SciencesLittle RockUSA
  3. 3.University of Mississippi Medical CenterJacksonUSA

Personalised recommendations